We found that sorafenib antitumor efficacy was improved in YAP-activated HCC cells with enhanced lipid ROS generation, since YAP activation sensitized confluent HCC cells to ferroptosis induced by sorafenib. This evidence concerns the gene YAP1 and hepatocellular carcinoma.